New horizons in pharmaceutical regulation

被引：8

作者：

Breckenridge, Alasdair ^{[1
]}

Mello, Michelle ^{[2
]}

Psaty, Bruce M. ^{[3
]}

机构：

[1] Med & Healthcare Prod Regulatory Agcy, London SW1W 9SZ, England

[2] Harvard Univ, Cambridge, MA 02115 USA

[3] Univ Washington, Med Epidemiol & Hlth Serv, Seattle, WA 98101 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 07期

关键词：

D O I：

10.1038/nrd3787

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

A life cycle approach to pharmaceutical regulation, in which the benefit-risk balance of new drugs continues to be robustly assessed following market approval, is emerging in both the United States and Europe. © 2012 Macmillan Publishers Limited. All rights reserved.

引用

页码：501 / 502

页数：2